Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial

A.H. Tavenier, R.S. Hermanides, E. Fabris, F. Lapostolle, J. Silvain, J.M. ten Berg, J.F. Lassen, L. Bolognese, W.J. Cantor, A. Cequier, M. Chettibi, S.G. Goodman, C.J. Hammett, K. Huber, M. Janzon, B. Merkely, R.F. Storey, U. Zeymer, P. Ecollan, J.P. ColletF.F. Willems, A. Diallo, E. Vicaut, C. Hamm, G. Montalescot, A.W.J. van 't Hof, ATLANTIC Investigators

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)65-74
Number of pages10
JournalThrombosis and Haemostasis
Volume120
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • abciximab
  • acute myocardial-infarction
  • bailout
  • eptifibatide
  • glycoprotein iib
  • high-dose tirofiban
  • iib-iiia inhibitors
  • iiia inhibitors
  • individual patients data
  • percutaneous coronary intervention
  • platelet inhibition
  • prehospital initiation
  • primary angioplasty
  • primary percutaneous coronary intervention
  • st-segment elevation
  • stemi
  • stent thrombosis
  • ticagrelor
  • tirofiban
  • IIIa inhibitors
  • HIGH-DOSE TIROFIBAN
  • STEMI
  • ACUTE MYOCARDIAL-INFARCTION
  • glycoprotein IIb
  • PRIMARY ANGIOPLASTY
  • STENT THROMBOSIS
  • IIB-IIIA INHIBITORS
  • INDIVIDUAL PATIENTS DATA
  • PERCUTANEOUS CORONARY INTERVENTION
  • PREHOSPITAL INITIATION
  • PLATELET INHIBITION
  • ST-SEGMENT ELEVATION

Cite this